GPT and insomnia measurement: Similarly, throughout the 24 weeks of observation in our study, no drug-induced renal injury or incidence of rash was reported except for a slight elevation in alanine transaminase (8.3% on naive-ANV vs. 15.9% on naive-EFV; 12.7% on Exp-ANV vs. 17.0% on Exp-EFV) (p > 0.05), neuropsychiatric events of insomnia (5% on naive-ANV vs. 8.0% on naive-EFV, p = 0.71; 0% on exp-ANV vs. 23.4% on exp-EFV, p < 0.001), and dizziness (6.7% on naive-ANV vs. 8.0% on naive-EFV, p = 0.77; 0% on exp-ANV vs. 25.5% on exp-EFV, p < 0.001).